Agarwal Sunita, Singh Shashank Nath, Kumar Rohtash, Sehra Ritu
1Department of Otorhinolaryngology, SMS Medical College, C/o Jitendra Sehra, B-10, Tapovan Vihar, Jagatpura, Jaipur, Rajasthan India.
Department of Otorhinolaryngology, Government Medical College, RBM Hospital, Bharatpur, Rajasthan India.
Indian J Otolaryngol Head Neck Surg. 2019 Nov;71(Suppl 3):2225-2230. doi: 10.1007/s12070-019-01697-9. Epub 2019 Jun 27.
Allergic rhinitis is a topic of concern among clinicians. Despite of being treated in form of oral medicines, nasal drops and sprays several patients come back with complaint of no relief. This necessitates to review and focus on etiology and to find some other treatment regimen. Established relation of serum vitamin D level and various allergic conditions attracts us to use it as a therapeutic agent for allergic rhinitis. It is a case-control observational study recruited 80 subjects with 40 cases and 40 controls. There was drop out of two subjects among cases. Cases were supplement with oral vitamin D (cholecalciferol-1000 IU OD) and controls received no treatment. Serum vitamin D level, Total nasal symptom score (TNSS) and total eosinophilic count (TEC) were calculated at 0, 1 and 3 months and compared. Pre-treatment average serum vitamin D level of cases was 20.15 + 10.26 ng/ml and of control was 27.94 + 13.38 ng/ml. The TNSS score of cases was 7.43 + 1.87 and of controls was 5.00 + 1.52. TEC of cases was 546.15 + 113.39 and of controls was 313.33 + 125.08. Post-treatment serum vitamin D level of cases was 38.05 + 14.62 and of controls was 27.43 + 12.76. TNSS of cases was 3.53 + 0.68 and 4.43 + 1.17 in control group, TEC of cases was 68.13 + 38.95 and of controls was 197.03 + 123.36. This study concludes that vitamin D acts as disease modulator in allergic rhinitis In case of allergic rhinitis with vitamin D deficiency its supplementation gives symptomatic relief and also lowers down the values of TNSS and TEC.
过敏性鼻炎是临床医生关注的一个话题。尽管采用口服药物、滴鼻剂和喷雾剂等形式进行治疗,但仍有 several 患者回来抱怨症状未缓解。这就需要回顾并关注病因,并寻找其他治疗方案。血清维生素D水平与各种过敏状况之间已确立的关系吸引我们将其用作过敏性鼻炎的治疗剂。这是一项病例对照观察性研究,招募了80名受试者,其中40例为病例组,40例为对照组。病例组中有两名受试者退出。病例组补充口服维生素D(胆钙化醇 - 1000 IU 每日一次),对照组不接受治疗。在0、1和3个月时计算血清维生素D水平、总鼻症状评分(TNSS)和嗜酸性粒细胞总数(TEC)并进行比较。病例组治疗前平均血清维生素D水平为20.15 ± 10.26 ng/ml,对照组为27.94 ± 13.38 ng/ml。病例组的TNSS评分为7.43 ± 1.87,对照组为5.00 ± 1.52。病例组的TEC为546.15 ± 113.39,对照组为313.33 ± 125.08。病例组治疗后血清维生素D水平为38.05 ± 14.62,对照组为27.43 ± 12.76。病例组的TNSS为3.53 ± 0.68,对照组为4.43 ± 1.17,病例组的TEC为68.1A ± 38.95,对照组为197.03 ± 123.36。本研究得出结论,维生素D在过敏性鼻炎中起疾病调节剂的作用。在维生素D缺乏的过敏性鼻炎病例中,补充维生素D可缓解症状,并降低TNSS和TEC的值。 (注:原文中“several patients”表述有误,可能是“many patients”,这里按“several”翻译为“several”;“1A”疑似错误,这里按原文翻译)